Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2024 | Looking forward to the Miami Myeloma MRD Virtual Meeting 2024

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, Miami, FL, outlines the agenda for the upcoming Miami Myeloma MRD Virtual Meeting, which will take place on 9 May 2024. The meeting is hosted by the Myeloma Institute at Sylvester Comprehensive Cancer Center at the University of Miami in partnership with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma. Topics will include the current era of measurable residual disease (MRD) testing, technologies for tracking MRD in myeloma, and myeloma MRD testing in the real-world setting. Importantly, Dr Nicole Gormley of the US Food and Drug Administration (FDA) will speak on the current perspectives of the FDA surrounding MRD and what the next steps are following the recent Oncologic Drugs Advisory Committee (ODAC) meeting, in which MRD was deemed an appropriate endpoint in clinical trials to accelerate the approval of novel therapies in myeloma. This interview took place at the 17th International Workshop on Myeloma (iwMyeloma) in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.